Pfizer Trovan Suspension Recommended In EU; Distribution Limited In U.S.
Executive Summary
A 12-month suspension of Pfizer's Trovan has been recommended by the European Union's Committee for Proprietary Medicinal Products. Pfizer plans to appeal the decision.
You may also be interested in...
Medical Advances Get More Chances When Safety Issues Arise
Withdrawn “me too” NMEs were removed from the market sooner after post-marketing safety signals than first-in-class or advance-in-class NMEs, showing the importance of available alternative therapy (or the lack thereof) in post-marketing risk management decisions.
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
FDA's Phase IV tracking system shows a 20% completion rate for postmarketing commitments
FDA Launches Phase IV Tracking System; Baseline Is 20% Completion Rate
FDA's Phase IV tracking system shows a 20% completion rate for postmarketing commitments